Biolog Inc.

Hayward, CA, United States

Biolog Inc.

Hayward, CA, United States

Time filter

Source Type

The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the automated microbiology market during the next five years. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide. This comprehensive 3-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies. - Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Alifax, Anagen, BD, Beckman Coulter/Danaher, Biochem, Biolog, bioMerieux, Bio-Rad, Biotrol, Cepheid, Curetis, GenMark, Hologic/Gen-Probe, HTG, Iris, J&J, Labsystems, Life Technologies, MiDI, Olympus, Qiagen, Roche, Siemens, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers. - Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market. - Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D. - Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years. - Potential market entry barriers and risks. Download the full report: https://www.reportbuyer.com/product/4933629/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/north-america-automated-microbiology-market-2021-usa-canada-mexico--supplier-shares-and-strategies-volume-and-sales-segment-forecasts-for-100-molecular-diagnostic-microbial-identification-300469516.html


The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the automated microbiology market during the next five years. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide. This comprehensive 7-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies. - Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Alifax, Anagen, BD, Beckman Coulter/Danaher, Biochem, Biolog, bioMerieux, Bio-Rad, Biotrol, Cepheid, Curetis, GenMark, Hologic/Gen-Probe, HTG, Iris, J&J, Labsystems, Life Technologies, MiDI, Olympus, Qiagen, Roche, Siemens, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers. - Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market. - Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D. - Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years. - Potential market entry barriers and risks. Read the full report: http://www.reportlinker.com/p04933627/Latin-America-Automated-Microbiology-Market-A-7-Country-Analysis-Supplier-Strategies-Volume-and-Sales-Forecasts-for-100-Molecular-Diagnostic-Microbial-Identification.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com   __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/latin-america-automated-microbiology-market-2021-a-7-country-analysis--supplier-strategies-volume-and-sales-forecasts-for-100-molecular-diagnostic-microbial-identification-300470303.html


Dublin, July 20, 2017 (GLOBE NEWSWIRE) -- The "Chitin and Chitosan Derivatives: Technologies, Applications and Global Markets" report has been added to Research and Markets' offering. The Global Chitin and Chitosan Market Should Reach $4.2 Billion by 2021 from $2.0 Billion in 2016 at a CAGR of 15.4% Chitin and chitosan derivatives are naturally occurring polymers with a wide range of applications. Due to the wide availability of the raw material used to obtain chitin and chitosan derivatives, demand for these products has increased recently. To provide a better understanding of the market, the market is segmented on the basis of product and application. Major products included in the report are chitin, chitosan, glucosamine and other derivatives. The application markets covered in the report are healthcare, biotechnology, animal food, agriculture, water treatment, food and beverage and water treatment. The report also covers the subsegments and related markets of the application markets above. The raw materials and key technologies used in the chitin and chitosan derivatives market are also covered at length. All of the product and application markets are further segmented by geographic region. The major geographic regions covered in the report are North America, South America, Europe, Asia-Pacific and the rest of the world (RoW), which includes Morocco, Egypt, South Africa and other African countries. A country-specific breakdown of the market for chitin and chitosan derivatives is also included in the report. Estimated values used are based on manufacturers' total revenues. The study covers the global market for chitin and chitosan derivatives and is not limited to the countries included in this report. The selection of the countries to be included in this report was mainly based on the total revenue generated from the sale of chitin and chitosan derivatives. The competitive landscape of the global market for chitin and chitosan derivatives is discussed and includes profiles of the major companies and their product portfolios. All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2016 to 2021 and assessing the competitors and competitor market shares. Report Includes - An overview of the chitin and chitosan derivatives market. - Analyses of global market trends, with data from 2015, 2016 and projections of compound annual growth rates (CAGRs) through 2021. - Segmentation of the market on the basis of products, applications and region. - In-depth coverage of the market dynamics, technology trends, drivers, constraints, and key strategies. - A look at key innovation in chitin and chitosan markets and discussion of applications of chitin and chitosan derivatives. - Profiles of major players in the industry. Key Topics Covered: 1: Introduction 2: Summary - Chitin And Chitosan: History And Current Market Trend 3: Overview - Key Drivers Of The Chitin And Chitosan Market - Key Market Restraints - Opportunities - Regulations 4: Market By Product - Chitin - Chitosan - Glucosamine - Others 5: Market By Industry Application - Healthcare - Biotechnology - Animal Food - Agriculture - Water Treatment - Food And Beverages - Personal Care Products 6: Regional Market Analysis 7: Company Profiles - Advanced Biopolymers AS - Agratech International Inc. - Bio21 - Biolog Heppe GMBH - Biophrame Technologies - Cargill Inc. - Chitosanlab - Dainichiseika Color & Chemicals Mfg. Co. Ltd. - Fengrun Biochemical Co. Ltd. - Fmc Health And Nutrition - France Chitine - Golden-Shell Pharmaceutical Co. Ltd. - GTC Bio Corp. - Heppe Medical Chitosan Gmbh - Jiangsu Aoxin Biotechnology Co. Ltd. - Kawaken Fine Chemicals Co. Ltd. - Kiomed Pharma - Kitozyme S.A. - Kunpoong Bio Co. Ltd. - Mahtani India Pvt. Ltd. - Marshall Marine Products - Meron Biopolymers - Nano3Bio - Novamatrix - Panvo Organics Pvt. Ltd. - Pelican Biotech & Chemicals Labs Pvt. Ltd. - Primex EHF - Prospec - PT Biotech Surindo - Shrividya Enterprises - Thahira Chemicals - TSI Group Ltd. - Vietnam Food (VNF) - Wellmune - Wisapple Biotech - Xianju Tengwang Chitosan Factory - Yang Zhou Rixing Biotech Co. Ltd. - Zhejiang Aoxing Biotechnology Co. Ltd. - Zhengzhou Kaibang Biotechnology Co. Ltd. For more information about this report visit https://www.researchandmarkets.com/research/3k3prh/chitin_and


The report on global RFID Blood Monitoring Systemmarket is a comprehensive study of demand, market size, forecasts, trends and factors affecting the global RFID Blood Monitoring Systemmarket. Moreover, the report is collective presentation of primary and secondary research findings. In addition, it provides deep insights on the factors that driving, restraining the global RFID Blood Monitoring System market. Porter's five forces model in the report provides insights into the competitive rivalry in the global RFID Blood Monitoring Systemmarket over the period of 2015 – 2023. Further, IGR- Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider. Research methodology • Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. • Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include • Company reports and publications • Government/institutional publications • Trade and associations' journals • Databases such as WTO, OECD, and World Bank, among others. • Websites and publications by research agencies Report Findings 1) Drivers • Increasing awareness among hospitals and blood banks in RFID enabled blood storage • Increasing incidence of chronic disease • Rising blood transfusions 2) Restraints • Stringent government regulations • High initial cost associated with the installation and maintenance of RFID systems 3) Opportunities • Increase in R&D activities regarding RFID systems • Growing adoption of RFID based solutions Segments Covered 1) Global RFID Blood Monitoring System market by Product types a. Systems b. Tags 2) Global RFID Blood Monitoring System market by End Users a. Blood Banks b. Hospital Blood Centres Companies profiled: The companies covered in the report include o Biolog-id o Mediware Information System o Honeywell o Nordic ID o TAGSY RFID o Zebra Technologies Wave Mark o Log Tag o Terso Solutions o RFID Group o Solstice Medical LLC o Stanley Innerspace o Logi Tag and Mobile Aspects Inc. o Magellan Technologies o SATO Vicinity. Reasons to buy this report 1) Comprehensive analysis of global as well as regional markets of RFID Blood Monitoring System 2) Complete coverage of all the product type and applications segments to analyze the trends, developments in RFID Blood Monitoring Systemmarket, and forecast of market size up to 2023. 3) Comprehensive analysis of the companies operating in RFID Blood Monitoring Systemmarket. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4) Infinium Global Research- Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify. Read the full report: http://www.reportlinker.com/p04947556/RFID-Blood-Monitoring-System-Market-Global-Industry-Analysis-Trends-Market-Size-Forecasts-to.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com


News Article | November 8, 2016
Site: www.marketwired.com

HAYWARD, CA--(Marketwired - November 08, 2016) - Biolog, Inc., a leader in the field of High Resolution Cell Phenotyping, announced that it has expanded its team by adding two veterans of the life sciences tools space. In August, Biolog elected David Weber to its Board of Directors. David has over 35 years of commercial experience across the life sciences industry with companies such as Pharmacia Biotech, Amersham Biosciences, Chemdex, Stratagene, and Eksigent Technologies. Prior to its recent acquisition by Thermo Fisher Scientific, David served as Executive Vice President and Chief Commercial Officer for Affymetrix and was instrumental in the company's turnaround. Today, Biolog announces the appointment of Richard Mabe to the position of Vice President of Sales and Marketing. Richard has had an extensive career in the life sciences industry with companies such as DuPont, Amersham International, GE Healthcare, and Sequenom. Richard's long track record of success in building and developing commercial teams will have significant impact on Biolog's business. "I am confident that the appointment of two industry veterans like David and Richard will enhance our already successful business and position Biolog for rapid and sustained growth," said Barry Bochner Ph.D., Biolog's Chief Executive Officer. "I am thrilled to welcome them into Biolog." Biolog is embarking on the release of exciting new products in the areas of microbial identification and characterization, and human cell and mitochondrial analysis. This is triggering an expansion and focus on the company's commercial initiatives. Biolog is a privately-held company based in Hayward, CA, that continues to lead in the development of powerful new cell analysis tools for solving critical problems in biological, pharmaceutical, and biotechnological research and development. It is the world leader in phenotypic cell profiling. Biolog products are available worldwide, either directly from the company or through its extensive network of international distributors. Further information can be obtained at Biolog's website, www.biolog.com.


Bochner B.R.,Biolog Inc. | Siri M.,Biolog Inc. | Siri M.,University of Colorado at Denver | Huang R.H.,Biolog Inc. | And 5 more authors.
PLoS ONE | Year: 2011

Background: To elucidate metabolic changes that occur in diabetes, obesity, and cancer, it is important to understand cellular energy metabolism pathways and their alterations in various cells. Methodology and Principal Findings: Here we describe a technology for simultaneous assessment of cellular energy metabolism pathways. The technology employs a redox dye chemistry specifically coupled to catabolic energy-producing pathways. Using this colorimetric assay, we show that human cancer cell lines from different organ tissues produce distinct profiles of metabolic activity. Further, we show that murine white and brown adipocyte cell lines produce profiles that are distinct from each other as well as from precursor cells undergoing differentiation. Conclusions: This technology can be employed as a fundamental tool in genotype-phenotype studies to determine changes in cells from shared lineages due to differentiation or mutation. © 2011 Bochner et al.


Bochner B.,Biolog Inc. | Gomez V.,Biolog Inc. | Ziman M.,Biolog Inc. | Yang S.,Oak Ridge National Laboratory | Brown S.D.,Oak Ridge National Laboratory
Applied Biochemistry and Biotechnology | Year: 2010

In this study, we developed a Phenotype MicroArray™ (PM) protocol to profile cellular phenotypes in Zymomonas mobilis, which included a standard set of nearly 2,000 assays for carbon, nitrogen, phosphorus and sulfur source utilization, nutrient stimulation, pH and osmotic stresses, and chemical sensitivities with 240 inhibitory chemicals. We observed two positive assays for C-source utilization (fructose and glucose) using the PM screen, which uses redox chemistry and cell respiration as a universal reporter to profile growth phenotypes in a high-throughput 96-well plate-based format. For nitrogen metabolism, the bacterium showed a positive test results for ammonia, aspartate, asparagine, glutamate, glutamine, and peptides. Z. mobilis appeared to use a diverse array of P-sources with two exceptions being pyrophosphate and tripolyphosphate. The assays suggested that Z. mobilis uses both inorganic and organic compounds as S-sources. No stimulation by nutrients was detected; however, there was evidence of partial inhibition by purines and pyrimidines, NAD, and deferoxamine. Z. mobilis was relatively resistant to acid pH, tolerating a pH down to about 4.0. It also tolerated phosphate, sulfate, and nitrate, but was rather sensitive to chloride and nitrite. Z. mobilis showed resistance to a large number of diverse chemicals that inhibit most bacteria. The information from PM analysis provides an overview of Z. mobilis physiology and a foundation for future comparisons of other wild-type and mutant Z. mobilis strains. © Humana Press 2009.


Boccuto L.,Greenwood Genetic Center | Chen C.-F.,Greenwood Genetic Center | Pittman A.R.,Greenwood Genetic Center | Skinner C.D.,Greenwood Genetic Center | And 5 more authors.
Molecular Autism | Year: 2013

Background: Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined. Several biochemical markers have been associated with ASDs, but there is still no laboratory test for these conditions. Methods. We analyzed the metabolic profile of lymphoblastoid cell lines from 137 patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays. Results: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source. The results correlated with the behavioral traits associated with either syndromal or non-syndromal autism, independent of the genetic background of the individual. The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits. Analysis of a previous small gene expression study found abnormal levels for some genes involved in tryptophan metabolic pathways in 10 patients. Conclusions: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis. In addition, quinolinic acid is the structural precursor of NAD§ssup§+§esup§, a critical energy carrier in mitochondria. Also, the serotonin branch of the tryptophan metabolic pathway generates NADH. Lastly, the levels of quinolinic and kynurenic acid are strongly influenced by the activity of the immune system. Therefore, decreased tryptophan metabolism may alter brain development, neuroimmune activity and mitochondrial function. Our finding of decreased tryptophan metabolism appears to provide a unifying biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs. © 2013 Boccuto et al.; licensee BioMed Central Ltd.


Toxin production is a central issue in the pathogenesis of Clostridium difficile and many other pathogenic microorganisms. Toxin synthesis is influenced by a variety of known and unknown factors of genetics, physiology, and environment. To facilitate the study of toxin production by C. difficile, we have developed a new, reliable, quantitative, and robust cell-based cytotoxicity assay. Then we combined this new assay with Phenotype MicroArrays (PM) technology which provides high throughput testing of culture conditions. This allowed us to quantitatively measure toxin production by C. difficile type strain ATCC 9689 under 768 culture conditions. The culture conditions include different carbon, nitrogen, phosphorus, and sulfur sources. Among these, 89 conditions produced strong toxin induction and 31 produced strong toxin repression. Strong toxin inducers included adenine, guanosine, arginine dipeptides, γ-D-Glu-Gly, methylamine, and others. Some leucine dipeptides and the triple-leucine tripeptide were among the strongest toxin repressors. While some results are consistent with previous observations, others are new observations that provide insights into toxin regulation and pathogenesis of C. difficile. Additionally, we have demonstrated that this combined assay technology can be applied broadly to a wide range of toxin producing microorganisms. This study is the first demonstration of simultaneous assessment of a large number of culture conditions influencing bacterial toxin production. The new functional cytotoxin quantitation method developed provides a valuable tool for studying toxigenic microorganisms and may also find applications in clinical and epidemiological research. © 2013 Lei, Bochner.


The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as Clostridium difficile, release toxins resulting in tissue and organ damage and death, even after antibiotic therapy that either reduces or eliminates the bacteria. In particular, various peptides, polypeptides, and proteins are disclosed herein that either inactivate Clostridium difficile toxin and/or reduce Clostridium difficile toxin production.

Loading Biolog Inc. collaborators
Loading Biolog Inc. collaborators